-----Original Message-----
From: michael marty
Sent: Wednesday, November 19, 2008 3:40 PM
To: cancercure@yahoogroups.com
Subject: [cancercure] Hope, for those with cancer

Cancer Cured For Good

By Bill Sardi and Timothy Hubbell
October 2008


It works 100% of the time to eradicate cancer completely, and cancer
does not recur even years later. That is how researchers describe the
most convincing cancer cure ever announced.

The weekly injection of just 100 billionths of a gram of a harmless
glyco-protein (a naturally-produced molecule with a sugar component
and a protein component) activates the human immune system and cures
cancer for good, according to human studies among breast cancer and
colon cancer patients, producing complete remissions lasting 4 and 7
years respectively. This glyco-protein cure is totally without side
effect but currently goes unused by cancer doctors.

Normal Gc protein (also called Vitamin-D binding protein) , an
abundant glyco-protein found in human blood serum, becomes the
molecular switch to activate macrophages when it is converted to its
active form, called Gc macrophage activating factor (Gc-MAF). Gc
protein is normally activated by conversion to Gc-MAF with the help
of the B and T cells (bone marrow-made and thymus gland-made white
blood cells). But, as researchers explain it themselves, cancer cells
secrete an enzyme known as alpha-N-acetylgalactosaminidase (also
called Nagalase) that completely blocks conversion of Gc protein to
Gc-MAF, preventing tumor-cell killing by the macrophages. This is the
way cancer cells escape detection and destruction, by disengaging the
human immune system. This also leaves cancer patients prone to
infections and many then succumb to pneumonia or other infections.

The once-weekly injection of minute amounts of Gc-MAF, just 100
nanograms (billionths of a gram), activates macrophages and allows
the immune system to pursue cancer cells with vigor, sufficient to
produce total long-term cures in humans.

Nobuto Yamamoto, director of the Division of Cancer Immunology and
Molecular Biology, Socrates Institute for Therapeutic Immunology,
Philadelphia, Pennsylvania, says this is "probably the most potent
macrophage activating factor ever discovered."


Once a sufficient number of activated macrophages are produced,
another Gc-MAF injection is not needed for a week because macrophages
have a half-life of about six days. After 16-22 weekly doses of Gc-
MAF the amount of Nagalase enzyme fell to levels found in healthy
people, which serves as evidence tumors have been completely
eliminated. The treatment was fool-proof - - - it worked in 100% of
16 breast cancer patients and there were no recurrent tumors over a
period of 4 years, says a report in the January 15 issue of the
International Journal of Cancer. [International Journal Cancer.2008
January15; 122(2):461-7]

In another startling follow-up report by Dr. Yamamoto and colleagues,
published in the upcoming July issue of Cancer Immunology
Immunotherapy, Gc-MAF therapy totally abolished tumors in 8 colon
cancer patients who had already undergone surgery but still exhibited
circulating cancer cells (metastases). After 32-50 weekly
injections, "all colorectal cancer patients exhibited healthy control
levels of the serum Nagalase activity, indicating eradication of
metastatic tumor cells,"said researchers, an effect that lasted 7
years with no indication of cancer recurrence either by enzyme
activity or CT scans, said researchers. [Cancer Immunology,
Immunotherapy Volume 57, Number 7 / July 2008] Published in an early
online edition of this journal, this confirming report has received
no attention by the new media so far, despite its striking
importance.

Gc-MAF treatment for cancer has been agonizingly slow to develop. Dr.
Yamamoto first described this immuno-therapy in 1993. [The Journal of
Immunology, 1993 151 (5); 2794-2802]

In a similar animal experiment published in 2003, researchers in
Germany, Japan and the United States collaborated to successfully
demonstrate that after they had injected macrophage activating factor
(Gc-MAF) into tumor-bearing mice, it totally eradicated tumors.
[Neoplasia 2003 January; 5(1): 32�40]

In 1997 Dr. Yamamoto injected GcMAF protein into tumor-bearing mice,
with the same startling results. A single enzyme injection doubled
the survival of these mice and just four enzyme injections increased
survival by 6-fold. [Cancer Research 1997 Jun 1; 57(11):2187-92]

In 1996 Dr. Yamamoto reported that all 52 cancer patients he had
studied carried elevated blood plasma levels of the immune
inactivating alpha-N-acetylgalactosaminidase enzyme (Nagalase),
whereas healthy humans had very low levels of this enzyme. [Cancer
Research 1996 Jun 15; 56(12):2827-31]

In the early 1990s, Dr. Yamamoto first described how the human immune
system is disengaged by enzymes secreted from cancer cells, even
filing a patent on the proposed therapy. [US Patent 5326749, July
1994; Cancer Research 1996 June 15; 56: 2827-31]

Activated Gc protein has been used in humans at much higher doses
without side effect. This Gc macrophage activating factor (Gc-MAF)
has been shown to be effective against a variety of cancers including
breast, prostate, stomach, liver, lung, uterus, ovary, brain, skin,
head/neck cancer, and leukemia.

Although GcMAF is also called Vitamin-D binding protein, the
activation of macrophages does not require Vitamin D.

It cannot be said the Gc-MAF cancer cure has gone unheralded. Reuters
News covered this developing story in January. But the news story
still did not receive top billing nor did it fully elucidate the
importance of the discovery, actually made years ago, that the human
body is capable of abolishing cancer once its immune system is
properly activated.

GcMAF is a naturally made molecule and is not patentable, though its
manufacturing process is patent protected. There is no evidence of
any current effort to commercialize this therapy or put it into
practice. Should such an effective treatment for cancer come into
common practice, the income stream from health-insurance plans for
every oncology office and cancer center in the world Would likely be
reduced to the point of financial insolvency and hundreds of
thousands of jobs would be eliminated.

The National Cancer Institute estimates cancer care in the U.S. costs
~$72 billion annually (2004). Furthermore, about $55 billion of
cancer drugs are used annually, none which have not significantly
improved survival rates throughout the history of their use. If a
typical cancer patient had to undergo 30 GcMAF injections at a cost
of $150 per injection, that would cost ~$4500, not counting doctor's
office visits and follow-up testing. For comparison, gene-targeted
cancer drugs range from $13,000 to $100,000 in cost per year and
produce only marginal improvements in survival (weeks to months).
[Targeted Oncology 2007 April, 2 (2); 113-19]

Up to this point, the National Cancer Institute is totally silent on
this discovery and there is no evidence the cancer care industry
plans to quickly mobilize to use this otherwise harmless treatment.

- -

Based in Southern California, Bill Sardi is a notedand well-known
author, lecturer, speaker, and health researcher, with numerous books
and articles to his credit. He can be reached at BSardi@....
Timothy Hubbell, a biochemist from Cincinnati, first called attention
to this discovery and provided consultation on the biochemistry.





[Non-text portions of this message have been removed]